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Abstract
Background: The chronic periodontitis is a highly prevalent disease that affects over 60% of people older
than 65 and 10-15% is a prevalence of severe form. The Scaling and root planing procedure (SRP) is a
gold standard of periodontal treatment which effectiveness was proven through numerous longitudinal
studies. The nature of this treatment is to mechanically disrupt bacterial biofilm, remove subgingival
calculus, and infected cement layer from the affected root surface to create favorable conditions for
repair and regeneration. Different adjunctive therapies are utilized to further improve outcomes with a
range of 0.2-0.6 mm of CAL improvement (compared to SRP alone). Local delivery minocycline
microspheres were extensively investigated and showed a statistically significant difference in a mean
reduction of PD compared to SRP alone. The objective of the present study is to assess the efficacy of
adjunctive therapy with minocycline microspheres in dental school settings measured in mean probing
depth reduction.
Material and methods. 1660 patients were included in the present study. 540 patients for the test group
and 1130 patients for the control group were identified through an automated search. Clinical and
demographic data were extracted and analyzed. Mean PD reduction and BOP reduction was calculated
for test and control groups as well as for subgroups based on the criteria of health history (smoking,
diabetes, cardiovascular disease, arthritis), disease severity (initial probing depth, ADA case type).
Percentages of sites reached the threshold of PD reduction of 1 and 2 mm were calculated for subgroups
stratified by the initial PD and compared in test and control groups.
Results: For the Arestin group, mean short-term PD reduction was 1.14 mm, and long-term PD reduction
was 1.18 mm. BOP reduction for the test group was 10.6% in the short-term follow-up and
- 4.24% for a long-term period.
Results: Control group showed a PD reduction of 1.2 mm for the short-term period and 1.5 mm for the
long-term. BOP reduction was 12.95% for the short-term period and 8.19% for the long-term follow up,
which was significantly higher than in the test group. Although the long-term PD reduction was
significantly greater in the Control group, the difference in short-term PD reduction was not significant.
There were no statistically significant differences in the percentage of sites reached PD ≤ 4 mm between
test and control groups.
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ABSTRACT
ADJUNCTIVE THERAPY OF PERIODONTAL DISEASE WITH MINOCYCLINE
MICROSPHERES IN DENTAL SCHOOL SETTINGS: A RETROSPECTIVE CHART
REVIEW
Artem Shurduk
Yu Cheng Chang, DDS, MS, DMD
Background: The chronic periodontitis is a highly prevalent disease that affects over 60% of
people older than 65 and 10-15% is a prevalence of severe form. The Scaling and root planning
procedure (SRP) is a gold standard of periodontal treatment which effectiveness was proven
through numerous longitudinal studies. The nature of this treatment is to mechanically disrupt
bacterial biofilm, remove subgingival calculus and infected cement layer from the affected root
surface to create favorable condition for repair and regeneration. Different adjunctive therapies
are utilized to further improve outcomes with range 0.2-0.6 mm of CAL improvement (compared
to SRP alone). Local delivery minocycline microspheres were extensively investigated and
showed statistically significant difference in mean reduction of PD compared to SRP alone. The
objective of present study is to assess efficacy of adjunctive therapy with minocycline
microspheres in dental school settings measured in mean probing depth reduction.

Material and methods. 1660 patients were included into the present study. 540 patients for the
test group and 1130 patients for the control group were identified through an automated search.
Clinical and demographic data were extracted and analyzed. Mean PD reduction and BOP
reduction was calculated for test and control groups as well as for subgroups based on the criteria
of health history (smoking, diabetes, cardiovascular disease, arthritis), disease severity (initial
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probing depth, ADA case type). Percentages of sites reached threshold of PD reduction of 1 and
2 mm were calculated for subgroups stratified by the initial PD and compared in test and control
groups.
Results: For the Arestin group, mean short-term PD reduction was 1.14 mm and long-term PD
reduction was 1.18 mm. BOP reduction for test group was 10.6% in the short-term follow up and
- 4.24% for long-term period.

Results: Control group showed PD reduction of 1.2 mm for the short-term period and 1.5 mm for
the long-term. BOP reduction was 12.95% for the short-term period and 8.19% for the long-term
follow up, which was significantly higher than in the test group. Although the long-term PD
reduction was significantly greater in the Control group, the difference in short-term PD
reduction was not significant. There were no statistically significant differences in percentage of
sites reached PD ≤ 4 mm between test and control groups.
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CHAPTER 1. INTRODUCTION

1

Background and Study Rationale

The present study is a retrospective chart review. The study was reviewed and approved by the
IRB and was conducted in accordance with all applicable University of Pennsylvania human
subjects research requirements as well as applicable federal regulations.

1.1 Study Introduction
The chronic periodontitis is a highly prevalent disease that affects over 60% of people over the
age of 65 and 10-15% is a prevalence of severe form (Chapple et al., 2013). The Scaling and root
planning procedure (SRP) is a gold standard of periodontal treatment which effectiveness was
proven through numerous longitudinal studies (Lindhe et al., 1984), (Pihlstrom et al., 1983). The
nature of this treatment is to mechanically disrupt bacterial biofilm, remove subgingival calculus
and infected cement layer from the affected root surface to create favorable condition for repair
and regeneration. Different adjunctive therapies are utilized to further improve outcomes with
range 0.2-0.6 mm of CAL improvement (compared to SRP alone) (Smiley et al., 2015). Local
delivery minocycline microspheres were investigated in the multi-center RCT and revealed
statistically significant difference in mean reduction of PD compared to SRP alone and SRP +
placebo group (Williams et al., 2001). The rationale of present study is to assess efficacy of
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adjunctive therapy of local application of minocycline spheres for periodontal sites with residual
deep PD after initial therapy.

The study is based on data obtained during routine clinical examination and treatment of patients
with the periodontal disease performed by predoctoral providers in dental school settings. The
dental school settings provide more representative model for the efficacy of Arestin application
in actual clinical practice because procedure is performed by the diverse group of practitioners
rather than limited number of examiners.
1.2 Background and Relevant Literature and Data
The first comprehensive review paper on the adjunctive use of local delivery minocycline was
published in 1998 by Vandekerckhove et al. The minocycline is a semi-synthetic antibiotic of the
tetracycline group that showed promising results as an adjunct in treatment of periodontitis.
Local delivery formulation relies on the sustained release properties of a carrier and allows for
low-dose application. (Vanderkerckhove et al., 1998).

Different formulations were tested for optimal result. For example, films with 30% concentration
of minocycline were prepared from either ethanol of chloroform solution, were tested in-vivo
and in-vitro. Minocycline films showed sustained release and pilot clinical experiment showed
reduction of motile microorganisms in periodontal pockets in 48 hours. (Elkayam et al., 1988)

Commercially available ointment formulation with 2% minocycline HCl was also tested and
showed statistically significant added benefits in terms CAL gain and PD reduction compared
with SRP. A parallel study on 13 patients with baseline PD ≥5 mm was published in 1996 and

2

showed average 0.3 mm of probing depth reduction when ointment was used as an adjunct
compared to SRP. (Radvar et al., 1996). A larger study involving 52 participants with more
severe periodontal disease (baseline PD ≥7 mm) and designed as a and showed average PD
reduction of 3.1 mm in the test group (SRP + ointment) versus 2.1 mm PD reduction in the
control group (SRP + vehicle). The 1 mm difference in PD reduction reaches level of clinical
significance. Interestingly enough, minocycline ointment was applied 4 times in course of 4
weeks and results were measured in 12 weeks (van Steenberghe et al., 1993).

Formulation containing minocycline microspheres dispersed in the poly (glycolide-lactide)
polymer, which is biodegradable matrix providing slow and sustainable release, was developed
in Lederle Laboratories (NY, USA). Gel with micro-encapsulated minocycline was provided in
disposable plastic syringes containing 4 mg of mixture which is equivalent 1 mg of minocycline.
Microbiologic efficacy of this formulation was investigated in the study published in 1992 and
revealed microbiological plaque composition that was more favorable for maintaining
periodontal health. Specifically, the trial involved 30 participants with severe periodontal disease
(at least 2 sites with PD ≥7 mm in one quadrant) who were randomized into test group (SRP with
adjunctive use of minocycline microspheres) and control group (SPR with placebo powder). The
plaque samples were collected at the baseline, 1 month, 3 months and 6 months and evaluated
using dark-field microscopy to assess presence of spirochetes and motile rods. The cultivation
flora technique was used to evaluate plaque composition and reveal presence of periodontal
pathogens. The presence of yeasts was tested using selective agar media. As a result, the test
group showed significantly lower percentage of spirochetes at 1 and 3 months and it also showed
lower proportion of motile rods at 3 months compared with the test group. The study showed
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lower percentage of Bacteroides spp. and P. intermedia at 1, 3 months, and lower proportion of
E.corrodens at 3 months. Overall, microbiological response in the test group was more amenable
for periodontal health. (Okuda et al., 1992)

Clinical efficacy of formulation was investigated by Braswell in 1992 in a parallel study with 47
participants and revealed 0.4 mm greater clinical attachment gain in the group with SRP plus
minocycline group versus SRP alone. In contrary, a later study published in 1994 results of SRP
group showed greater CAL gain on the SRP group. The difference did not reach the level of
statistical significance. The study was designed as a split-mouth trial with 51 participants that
were randomized into 4 groups: minocycline, minocycline plus SRP, SRP alone and no
treatment. Researchers assessed both clinical and microbiological parameters. The only clinical
parameter that showed statistical significance was PD reduction in the MH+SRP group in 1
month. (Jones et al., 1994)

A large multi-center study was published in 2001 by Williams as a part Phase 3 clinical trial
(OPI-103A and 103B). This trial recruited 748 participants with moderate-to-advanced chronic
periodontitis who were randomized into 3 groups: SRP + Placebo, SRP + MH spheres, and SRP
alone as a control. As the primary outcome, investigators measured PD reduction with secondary
outcome parameters (clinical response, OR (odds ratio) to reduce PD to the level ≥5mm which
did not require further surgical therapy). The SRP + Arestin group reported a statistical
significance when compared with both the SRP and SRP + placebo groups. The mean PD
reduction for the SRP + MH group was 1.32mm, whereas the SRP + vehicle it was reported as
1.00 mm, and the SRP control group as 1.08 mm. The study additionally showed a greater
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efficacy of treatment in the smokers and the greater OR for PD reduction to the level of ≥5 mm
for groups with the baseline PD 5-7mm. (Williams et al., 2001)

The results of trials 103A and 103B were further investigated by Paquette in 2003. This group
mainly focused on the Arestin efficacy in smokers and followed the design of Williams study.
Data from 271 smoking patients was analyzed from the same groups: SRP + placebo, SRP +
minocycline and SRP alone as a control group. The difference in PD reduction was statistically
significant in 1, 6 and 9 months compared to the control group. The mean PD reduction in
smokers from SRP + MH group was 1.19 mm from baseline and for SRP alone group it was 0.9
mm (D. Paquette et al., 2003). As the result, minocycline microspheres were FDA approved and
routinely used in the clinical practice under brand name “Arestin” (Orapharma). (D. Paquette et
al., 2003)

The secondary analysis of the Phase 3 trials was further continued by the Paquette in 2004 and
mainly focused on the clinical response on the site-level. This study included 499 patients with
moderate to advanced chronic periodontitis who were randomized into 2 treatment arms: SRP
alone and SRP plus minocycline. Results showed that more sites treated with minocycline
reached probing depth lesser than 4 mm at both 1 and 3 months. Smokers and all population
showed similar results. The clinical response was more pronounced in the test group comparing
with the SRP alone. (D. W. Paquette et al., 2004)

Added benefits for patients with poorly controlled diabetes were described in the study published
by Skaleric et. al in 2004. This group included 20 patients with Type 1 Diabetes (HBA1C 7.5%)
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and chronic periodontitis, as defined by the presence of at least 4 teeth with PD ≥ 5 mm, were
enrolled in the study. All subjects received SRP at the baseline and patients in the test group
received an application of the minocycline microspheres in all sites with PD ≥ 5 mm at base line
and in 12 weeks. Clinical parameters that were evaluated included PD, CAL, PI, GI, and
HBA1C. The test group showed significantly greater PD reduction and CAL gain, however, the
difference in HBA1C levels was not statistically significant. (Skaleric et al., 2004)

The large post-marketing study of Arestin that was mainly focused on the efficacy of repeated
minocycline application, was conducted in the private practice setting in 2004 by Lessem and
Hanlon. A multi-center study with 895 participating dentists involved the treatment of 2805
patients who were allocated to two groups. All patients received SRP with adjunctive use of local
delivery minocycline at the baseline. The first group containing 1095 patients was evaluated in 3
months and received the second round of local delivery minocycline which was reevaluated
again in 6 months. The second group with 1710 patients received only one intervention and was
assessed in 6 months. Results for the first group provided mean probing depth reduction at 1.94
mm in 6 months, which was significantly greater than probing depth reduction of 1.82 mm for
the second group. Subgroups of patients with diabetes, smoking, and cardiovascular disease
showed similar results. 62% of treated sites decreased to ≤5 mm after the first treatment and for 2
treatments, this number reached 67%. (Lessem & Hanlon, 2004)

The long-term effect of the adjunctive therapy with local delivery minocycline was investigated
in a double-blind randomized control study that was published by Corelli et al. These researchers
recruited 26 patients into the analysis (59 initially enrolled) where the test group received SRP
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and minocycline at the baseline, 90, 180, 270, 360, and 720 days. The control group received
SRP + vehicle at the same time-points. As the result, the test group showed greater PD reduction
at the 270 and 360, although this result was not maintained at the 720 days. (Cortelli et al., 2006)

Microbiological evaluation of subgingival plaque after SRP and adjunctive use of minocycline
showed a statistically significant differences in the reduction of red and orange complex when
compared to samples of patients treated with the SRP alone. Clinically, the mean probing depth
reduction for the test group (1.38 mm) was significantly greater compared with the control (1.01
mm). BOP reduction was also significantly higher in the Arestin group (25.2% vs 13.8% for SRP
alone). (Goodson et al., 2007).

The difference in the microbiologic response in smokers was evaluated using the same patient
population as the Goodson study form 2007. A Combination of SRP and minocycline
microspheres showed a significant decrease of red complex bacteria and orange complex bacteria
in smokers. In contrast, SRP alone did not reduce number of red complex bacteria in current
smokers. (Grossi et al., 2007).

A study published by Hellstrom et al. in 2008 evaluated minocycline microspheres as an adjunct
for the surgical therapy of Periodontal disease. Researches included 60 patients with at least 2
non-molar periodontal sites with probing depth ≥ 6 mm located in different quadrants.
Participants were randomized in two groups where the control group (SO) received SRP at the
baseline and surgery (Modified Widman Flap) at weeks 2 and 4. The test group (SMM) received
SRP with minocycline placement at the baseline. At weeks 2 and 3 periodontal surgery
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(Modified Widman flap) was performed on different quadrants supplemented with the placement
of minocycline microspheres to all sites with PD ≥ mm including surgical sites each time. The
application of the Arestin was also repeated at week 5. At the 25 week record, clinical
parameters were reevaluated. The test group showed greater probing depth reduction in all
treated sites (2.51 ± 0.1 mm) compared with the control group (2.05 ± 0.1 mm). It is worth
noting that smokers from the test group exhibited significantly greater probing depth reduction
(2.3 ± 0.09 mm) than smokers from the control group (2.05 ± 0.09 mm). (Hellström et al., 2008)

An association of clinical response for the adjunctive treatment with minocycline microspheres
and antimicrobial activity was studied by the group of P. Bland in 2010. The clinical study was
conducted on 127 subjects with moderate-to-advanced chronic periodontitis who were randomly
assigned amongst two groups. The test group (62 patients) received SRP with the subgingival
application of minocycline microspheres which was compared with SRP alone (Control group –
65 patients). Microbiological (DNA analysis) and clinical parameters were compared at the
baseline and 30 day follow up. As the result, probing depth reduction significantly correlated
with the decrease of red complex bacteria. The test showed significantly greater improvement of
all clinical parameters compared to SRP alone. (Bland et al., 2010)

Comparison of clinical efficacy of adjunctive therapy of adjunctive use of local delivery
minocycline with a local application of 25% metronidazole gel and SRP alone was published in
2013. This study involved 20 participants with 60 periodontal sites. Minocycline group showed
significantly greater PD reduction (by 0.85% mm) when compared with SRP alone group, but
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the difference in PD reduction between other groups did not reach the level of statistical
significance. (Pandit et al., 2013)

The clinical effect of adjunctive therapy with minocycline during the maintenance phase was
evaluated by Killien and his group in 2016. 60 patients were allocated into 2 groups and were
followed for one year. All patients were in the maintenance phase of their treatment and after
receiving routine maintenance with selective SRP of the inflated sites, patients from the test
group also received the application of the minocycline microspheres. 9 patients were excluded
because of different reasons over the course of this study. As the result, all groups improved
clinical parameters without statistically significant differences between groups. The odds of
having greater BOP reduction were greater in the minocycline groups and also test group in 6
months showed a decrease in levels of IL1 in the gingival crevicular fluid. (Killeen et al., 2016)
The same trend was observed when patients were followed in 24 months. Radiographic
examination showed stable crestal bone level, improvement in probing depth was maintained,
but the difference between groups was not statistically significant. (Killeen et al., 2018)

The series of smaller clinical studies compared the efficacy of the local delivery minocycline
with other modalities of adjunctive therapy without any reported significant difference between
groups. A study that included 20 patients compared minocycline microspheres with the
“Periochip”, which is a local delivery formulation, containing 2.5 mg of chlorhexidine gluconate,
with 3 months follow up. (Jhinger et al., 2015) Photodynamic therapy was also compared with
adjunctive use of minocycline and SRP alone. 45 patients were enrolled and clinical parameters
were followed up for 12 months. (Tabenski et al., 2017)
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Overall, previous studies built extensive evidence supporting the implementation of minocycline
as an adjunct to non-surgical therapy during both initial and maintenance phases of periodontal
therapy. Arestin has been extensively used over the years, and a thorough analysis of the
available data can be a valuable addition to the existing evidence.
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CHAPTER 2. OBJECTIVES
2

Study Objectives

The purpose of this study is to evaluate the clinical effect of adjunctive therapy of chronic
periodontitis with minocycline microspheres (Arestin) in the dental school setting.

2.1 Primary Objective
The primary objective of this study is to determine the efficacy of minocycline microspheres by
measuring the mean PD reduction from the time of Arestin placement to the reevaluation and at
the time of the most recent observation. PD reduction was measured by subtraction of PD at the
reevaluation appointment from PD at the baseline (before MH application).
2.2 Secondary Objective
The secondary objectives of this study evaluated the clinical response which is defined as the
percentage of sites that reached a threshold of PD reduction of 1 and 2 mm, BOP reduction after
treatment which is the difference in the percentage of periodontal sites showing bleeding on
probing before and after treatment, percentage of sites reached the PD ≤4 mm, stratified by
initial probing depth, and calculation of the odds ratio for sites with different PD at the baseline
to improve to the number ≤4 mm which is considered a threshold for surgical periodontal
treatment. Also, the secondary objective included analysis of subgroups of patients based on
health history (smoking, diabetes, cardiovascular disease, arthritis) and the severity of
periodontal disease (case type).
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CHAPTER 3. MATERIALS AND METHODS

3

Material and Methods

3.1 Material
3.1.1 Total Number of Subjects
The study is a retrospective case-control study that included a retrospective review of a total of
1660 subjects. Subjects for test and control groups were determined by the automated search
using procedure codes in the EMR system. The sample size was a sample size of convenience
which means that all available cases that matched inclusion criteria were included in the present
study.
3.1.2 Inclusion Criteria

A total of 540 subjects were selected for the test group from the predoctoral clinic of Penn
Dental Medicine from 2016-2020. The test group was selected as those diagnosed with chronic
periodontitis and received periodontal treatment that included SRP with the adjunctive
application of Minocycline microspheres. The control group (1120 subjects) consisted of patients
from the same clinic who received 2 or more rounds of scaling and root planning on the same
tooth (quadrant) within a 1-year interval from 2016 to 2020.
3.1.3 Exclusion Criteria

Patients who received adjunctive therapy with minocycline for peri-implant sites or any
periodontal surgery were excluded. Subjects with incomplete follow-up data, such as missing
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periodontal charting during reevaluation or long-term follow-up appointment, were also
excluded. Furthermore, periodontal sites that were outside of the therapeutic range of PD 5-9 mm
were excluded from the analysis.
3.1.4 Variables

Age, gender, race, smoking history (past, present), diabetes (type, controlled, uncontrolled),
BMI, presence of CVD, and arthritis were extracted from the EMR system (Axium) and
combined into Demographic variables of the present study. Clinical variables were ADA case
type, the number of teeth treated with MH. PD, BOP, CAL for all treated sites at the baseline,
during revaluation, after MH placement, and at the most recent examination. Time interval
(days) from SRP (when it was done prior to minocycline application) to the MH placement, time
from MH placement to the reevaluation, and time from the baseline to the point of the most
recent observation (length of observation). Additionally, number of maintenance visits was
calculated for each patient in both groups to verify similar maintenance compliance in both
groups.

3.2 Methods

3.2.1 Data extraction

The automated search was performed on the EHR system and identified potential subjects for the
test group (patients who received treatment with the local delivery minocycline) or control group
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(patients who received repeated SRP for the same tooth/quadrant within a year). The dataset
contained both demographic and clinical variables that were exported from EHR software
(Axium) and imported into R-studio (version 1.2.5042). All included subjects were deidentified
and assigned with unlinked numerical identification codes. (Figure 3)
3.2.2 Data management

The next step was to identify specific periodontal sites that received treatment. All sites with PD
≥ 5 mm at the baseline were assumed to receive periodontal treatment and were included for
analysis. At this point, we applied filters for the exclusion of patients with missing observations
at the follow-up appointments. We excluded patients who received any surgical treatment of
periodontal disease and all periodontal sites with initial PD ≥ 9 mm were not analyzed. Probing
depth and bleeding of probing of treated sites was tracked across different appointments and
exported for predetermined timepoints.

For the control group, the first timepoint (“Initial” or T1) was periodontal charting that was
performed on the same day or with the shortest interval prior to the first round of SRP. The
second timepoint (“Short-term” or T2) coincided with the reevaluation appointment after the first
SRP. The last timepoint for the Control group (“Long-term” or T3) was the most recent
periodontal charting of the patient. (Figure 1).

The initial timepoint for the test group (“Minocycline placement” or T2) included PD and BOP
from the periodontal charting performed on the same day or immediately prior to the date when
local minocycline was applied. The data from the periodontal chart that immediately preceded
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the initial “Minocycline placement” timepoint was also extracted and included in the first
timepoint (“SRP” or T1). The periodontal charting from the reevaluation after minocycline
placement was used as the source of data for the third timepoint (“Short-term” or T3). For the
fourth timepoint (“Long-term” or T4), we analyzed the most recent periodontal chart available
for the patient. (Figure 2) It’s worth mentioning that since the main goal of this study was to
assess the clinical effect of Arestin, we did not exclude any subject who was missing data from
the periodontal charting prior to the Minocycline application (T1), and also some patients
received Arestin as the adjunct for their first round of SRP.

The clinical data were extracted for the treated sites into a new dataset and we calculated shortterm and long-term probing depth reduction for each periodontal site. The percentage of sites
exhibited positive bleeding on probing was also calculated for the initial timepoints and for
follow up appointments.

Additionally, we extracted datasets for the following subgroups of patients: Smokers, Nonsmokers, Diabetes, Cardiovascular disease, Arthritis, ADA periodontal case type 2, ADA
periodontal case type 3.
3.2.3 Data analysis
Descriptive statistics (mean PD reduction) was used to evaluate primary outcomes. A two-sided
Welch t-test with a 95% confidence interval was performed to compare results with the control
group. The analysis of covariance (ANCOVA) was implemented with posthoc pairwise
comparison and Bonferroni corrections to evaluate confounding factors. A proportion test was
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performed to compare demographic variables in the test and control group and to compare
percentages of sites with positive bleeding on probing.
Secondary outcomes included odds ratio to reduce PD <5 mm with 95% CI was calculated for
subgroups with initial PD ≥5 mm, ≥6 mm, and ≥7mm.
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CHAPTER 4. RESULTS
4

Results

4.1 Demographics

The demographics and clinical picture were similar in all groups with some minor differences.
The test group had a greater percentage of ASA 2 patients, patients with cardiovascular disease,
and patients with ADA case type 2. The control group had a greater percentage of smoking
patients. Demographic variables for the test and control group are summarized in Tables 1, 20,
46.

There were slightly more females than male subjects in the study (55.19% in the test group vs
51.96% in the control) and the biggest proportion was African American patients (38.15% in the
test group and 41.2% in the control). The mean age of participants was 61.5 years for the test
group and 62 for the control, age was ranging from 14 to 93 years. (Table 46)

Periodontal disease was assigned with case type 2 in 63.89% for the test group and 44.46% for
the control. Patients who had ADA periodontal case type 3 comprised 24.63% and 30.45% for
the test and control group respectively. Clinical profiles were very similar for the test and control
groups with the greatest number of treated periodontal sites on first and second maxillary molars,
followed by the mandibular molars. A total of 519 periodontal sites were analyzed in the test
group and 11,130 sites were included in analysis for the control group. The vast majority of
treated periodontal sites had an initial probing depth of 5 mm, followed by sites with an initial
PD of 6 mm and significantly fewer sites with deeper probing depth. 26.4% of sites in the test
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group showed positive bleeding on probing prior to the minocycline application, which was less
than in the control group (37.73%). The sites that were treated were predominantly interproximal
sites. Initial clinical presentation is summarized in Figures 5, 6, 7, 8, 15, 16, 17, 18.

The mean length of observation for “short-term result” was 112 and 150 days for the test and
control group respectively. “Long-term” follow-up was performed in 247 days on average for the
test group and 243 days for the control. When patients from the test group received SRP prior to
the minocycline application, the average interval between the first SRP and MH placement was
45 days. During the 3 years of observation from 2016-2020, patients from the test group received
2.13 maintenance visits on average (range 0-12) which was not significantly different (p=0.47)
than the number of maintenance visits that received by patients of the control group (2.19).
4.2 Clinical efficacy

Initial probing depth for the treated sites in the test group was 5.41 (± 0.03) mm. which
decreased to 4.27 (±0.06) after application of the Minocycline microspheres for short-term
follow up and mean probing depth for long-term follow up was 4.23 (±0.06) mm. (Figure 19,
Table 21). The difference in mean probing depth was statistically significant between initial
observation and short-term follow up. The difference between short-term follow-up and longterm follow-up did not reach the level of statistical significance in the test group.

Mean probing depth reduction in the test group for short-term follow-up was calculated as 1.14
(±0.06) mm and for long-term period it was 1.18 (±0.07) mm, which was not significantly

18

different from the short-term value (Figure 20, Table 22). BOP reduction for the short-term
period was 10.6% and it decreased to - 4.24% upon long-term reevaluation.

For the control group, the mean probing depth for the treated sites was 5.61 (±0.01) mm at the
initial examination and it decreased to 4.42 (±0.01) mm during short-term follow-up, which was
significantly different from the baseline. For long-term follow-up, mean probing depth was 4.12
(±0.01) mm, which was significantly different from both initial and short-term values. (Figure 9,
Table 2).

Mean short-term probing depth reduction was 1.20 (±0.01) mm, which became 1.50 (±0.01) mm
at the long-term follow-up and there was a statistically significant difference between short and
long-term mean PD reduction (p = 2.2e-16) (Figure 10, Table 3). The short-term BOP reduction
was 12.95% and long-term PD reduction was 8.19% for the control group.

In comparing probing depth reduction between test and control groups, the short-term PD
reduction did not reach statistical significance (1.14 and 1.2 mm respectively, Table 40). On the
contrary, the long-term reduction was significantly higher in the control group (1.18 mm versus
1.50 mm with p = 1.63e-6, Table 41). The percentage of sites with positive BOP was compared
using the proportion test and it was significantly higher in the control group at the baseline
(37.73% compared with 26.40% for the test group with p-value = 2.31e-07) and at the short-term
reevaluation (24.78% versus 15.8% for the test group with p-value = 9.64e-06). However, there
was no significant difference in the percentage of sites with BOP between the test and control
group in long-term follow-up. (30.64% and 29.54% respectively, Table 47).
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4.2 Subgroups analyses

4.2.1 Initial probing depth

For the subgroup of periodontal sites with initial PD = 5 mm (368 sites in the test group and
6967 sites in the control), mean short-term PD reduction was 0.93 and 0.99 for the test and
control group respectively and was not statistically significant between groups. A long-term PD
reduction was significantly greater in the control group (1.19 mm compared to 0.92 for the test
group, p-value = 0.0001).

Short-term PD reduction in the subgroup with initial PD = 6 mm (104 sites in the test group and
2356 sites in the control) was 1.37 and 1.31 on average for the test and control group, which was
not statistically significant. Long-term PD reduction followed the same trend and it was
calculated as 1.53 mm for the test group and 1.69 mm for the control group with no statistically
significant difference.

The subgroup with initial PD = 7 mm (34 sites in the test group and 1047 sites in the control)
showed mean short-term PD reduction 1.76 and 1.65 for test and control group respectively.
Long-term PD reduction was 2.5 mm for the test and 2.16 mm for the control. Again, the
difference between test and control groups within the subgroup was insignificant.

Mean short-term probing depth reduction for the subgroup with PD = 8 mm (12 sites in the test
group and 518 sites in the control) at the initial presentation was 2.5 mm in the test group and
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2.04 mm in the control group and the difference between groups did not reach the level of
statistical significance. The same pattern can be observed in the long-term PD reduction, which
was 2.08 in the test group and 2.72 in the control group (p-value = 0.3). Data obtained from
subgroups stratified by initial PD was summarized in Tables 16, 17, 36, 37, and Figures 11, 12,
21, 22.

4.2.1 Smoking

The mean short-term probing depth reduction in the smoking population was 1.13 mm and 1.15
mm for test and control groups respectively without statistically significant difference between
groups. Within the test groups, short-term PD reduction of smokers was not significantly
different from both mean short-term PD reduction of non-smokers (1.08±0.07 mm) and all
population (1.14±0.06 mm). For the control group, short-term PD reduction in smokers was
significantly less than in non-smokers (1.15 mm compared to 1.23 mm respectively with p-value
< 0.01), but when it was compared with all population (1.20 mm), there was no significant
difference.

The mean long-term PD reduction in smokers was 0.87 mm for the test group and 1.51 mm for
the control, and the difference was statistically significant (p<0.01). For the test group, the
difference between smokers and non-smokers was significant (0.87 mm versus 1.29 mm
respectively with p<0.01), but it was only marginal when smokers and all population were
compared (0.87 versus 1.18 mm with p-value=0.02 before Bonferroni correction). In the control
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group, the difference between subgroups did not reach the level of statistical significance.
(Tables 9, 10, 29, 30)

In the control group, 19.13% of sites in the test group and 38.53% sites showed positive bleeding
on probing in smokers at the baseline. These numbers decreased at the short-term reevaluation to
10.93% and 28.4% for test and control groups respectively. The measurements for positive
bleeding upon probing rebounded up to 33.33% in the test group and 26.37% in the control.
Therefore, short-term BOP reduction for smokers was 8.2% in the test group and 10.13% in the
control. Long-term BOP reduction for the smokers in the test group was – 14.20%, but in the
control, it slightly increased to 12.16%. (Table 47)

4.2.2 Diabetes

Short-term probing depth reduction in the subgroup of diabetic patients was 1.21±0.15 mm for
the test group and 1.11±0.03 for the control, which was significantly less than PD reduction for
all population in the control group (p<0.01), but not in the test group. Long-term PD reduction
was calculated as 1.37±0.17 mm and 1.44±0,04 mm for the test and control group respectively.
There was no statistically significant difference when the mean PD reduction of diabetes
subgroup was compared to all population. Inter-group comparison in diabetic between test and
control groups did not reveal any significant difference in both short-term and long-term PD
reduction. (Tables 9, 11, 29, 31).
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Positive bleeding on probing sign was found in 30.67% and 31.5% of sites within the subgroup
of patients with diabetes in the test and control group respectively during the initial presentation.
During the short-term reevaluation, 17.33% of sites in the test group and 26.86% of sites in the
control had positive BOP. For the long-term reevaluation, BOP rebounded to 26.44% in the test
group but showed slight improvement up to 25.73% in the control. The short-term BOP
reduction was 13.34% for the test group and 4.64% for the control. The long-term BOP reduction
in diabetic patients was recorded as 1.34% in the test group and 5.77% for the control. (Table 47)

4.2.3 Cardiovascular disease

The mean short-term PD reduction for patients who reported cardiovascular disease was
1.08±0.08 mm for the test group and 1.18±0.02 mm for the control without significant difference
amongst all populations. The long-term probing depth reduction was 1.33±0.1 mm and
1.44±0.04 mm for test and control groups respectively. The difference with all populations was
insignificant for the test group and it was marginally significant for the control group (p-value =
0.03 before Bonferroni correction). Comparing mean PD reduction between test and control
groups for the subgroup of patients with the cardiovascular disease did not show any significant
difference. (Tables 9, 12, 29, 32)

In the subgroup of patients with cardiovascular disease, 22.12% of sites in the test group had
positive BOP before treatment, while for the control group this number was 37.44%. During the
short-term reevaluation, BOP was found in 17.79% of sites in the test group and 24.5% of sites
in the control. At the long-term reevaluation, 26.44% and 29.61% of sites in test and control
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groups respectively exhibited positive bleeding on probing. Hence the short-term BOP reduction
was 4.33% for the test group and 12.94% in the control group. The long-term reduction showed a
rebound in both groups up to – 4.32% for the test and 7.83% for the control. (Table 47)

4.2.4 Arthritis

The subgroup of patients with arthritis showed a mean short-term PD reduction of 1.38±0.1 mm
in the test group and 1.15±0.02 mm in the control group, with the marginally significant
difference between groups (p=0.02 before Bonferroni correction). Comparing with all
population, the PD reduction in the test group was also marginally different (p=0.03 before
Bonferroni correction), but not in the control group. The long-term probing depth reduction was
1.26±0.02 mm for the test group and 1.38±0.02 for the control group. There was no significant
difference found in both inter-group comparison and intra-group comparison for the long-term
PD reduction in patients with Arthritis. (Tables 9, 13, 29, 33).

The arthritis subgroup showed 18.88% of sites with BOP in the test group before treatment,
which was significantly less than 34.89% for the control. At the short-term reevaluation, 11.73%
and 20.39% of sites expressed positive BOP, which rebounded in both groups to 24.49% for the
test and to 34.92% for the control. BOP reduction was 7.15% and 14.5% for test and control
groups respectively during the short-term re-evaluation. During the long-term follow-up, the test
group showed -5.61% of BOP reduction and control group showed -0.03%. (Table 47)

4.2.5 Case type

24

For the subgroup of patients with ADA periodontal case type 2, mean short-term probing depth
reduction was calculated as 1.13±0.06 mm and 1.24±0.02 for test and control groups respectively
and it was insignificantly different in both groups and when compared with all population.
The subgroup of patients with periodontal case type 3 showed mean short-term PD reduction of
1.20±0.14 mm for the test and 1.16±0.02 mm for the control. (Tables 9, 14, 29, 34)
A comparison of short-term PD reduction of Case type 2 and Case type 3 showed marginal
statistical significance for the control group (1.24 versus 1.16 for Type 3 with p-value=0.01
before Bonferroni correction), but not for the test group (1.13 for Type 2 and 1.20 for Type 3).

The long-term PD reduction for periodontal case type 2 was 1.19±0.09 mm in the test group and
1.48±0.02 mm for the control group a with statistically significant difference between test and
control groups (p<0.01). Both the test and control groups reported no significant difference with
all population and case type 3. The mean long-term PD reduction for Type 3 was 1.2±0.14 mm
for the test group and 1.48±0.02 mm for the control.

For case type 2, 25.29% of sites in the test group had positive BOP sign during the baseline
examination, compared with 35.55% in the control group. The short-term reevaluation revealed
BOP in 12.5% and 21.33% of sites for the test group and the control respectively. At the longterm follow up 27.33% of sites in the test group and 25% of sites in the control group had
positive BOP. Thus, the short-term BOP reduction was 12.79% and 14.22% in test and control
groups respectively. The long-term BOP reduction was -2.04% for the test group and 10.55% for
the control.
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For case type 3, 29.5% and 35.28% of sites had BOP before treatment in the test and control
group respectively, which decreased to almost identical 23% in the test group and 23.3% in the
control at the short-term reevaluation. Upon long-term follow-up, 35.5% of sites in the test group
and 30.47% of sites in the control showed positive BOP. Short-term BOP reduction was 6.5%
and 11.95% for test and control groups respectively, which rebounded to – 2.75% in the test
group and 4.81% in the control group.

4.3 Clinical response

In the present study, clinical response was defined as the percentage of sites that had probing
depth reduction greater or equal threshold of 1 and 2 mm. The clinical response was assessed on
the site level for groups with different baseline probing depths. We analyzed groups with initial
PD ≥ 5 mm, ≥ 6 mm, ≥ 7 mm. Proportions of sites with defined clinical responses were
compared and p-values were calculated using the proportion test.
For the subgroup with initial PD ≥ 5 mm (11,130 sites in the control group and 519 sites in the
test group), 70.71% of sites in the test group and 80.23% in the control group exhibited clinical
response ≥ 1 mm (had a probing depth reduction of 1 mm or greater). The difference was
statistically significant with p-value = 2.78e-08. Clinical response of ≥ 2 mm was found in
52.35% of sites in the control group and 42.96% of sites in the test group which was significantly
less (p-value = 5.06e-05) (Tables 18, 19, 38, 39. Figures 13, 23, 24, 25)

The subgroup with initial PD ≥ 6 mm (4163 sites for the control group and 151 sites in the test
group) showed a clinical response of ≥ 1 mm in 82.08% of sites in the control group and 77.48%
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of sites in the test group. 65% of sites in the control group and 60.92% of sites in the test group
reached the threshold of PD reduction of ≥ 2 mm. The difference between the test and control
group was insignificant for clinical responses ≥ 1 and ≥ 2 mm.

In the subgroup with initial PD ≥ 7 mm, 83.83% and 80.85% of sites for control and test groups
respectively showed clinical improvement regarding PD reduction of ≥ 1 mm. The threshold of ≥
2 mm was reached by 70.95% of sites in the control group and 70.21% of sited in the test group.
The difference between test and control also did not reach the level of clinical significance in the
subgroup with initial PD ≥ 7 mm.

4.4 Odds ratio
The probing depth less or equal to 4 mm is the important indicator of disease control. We
calculated the percentage of sites that reached PD ≥ 4 mm for each subgroup stratified by the
initial probing depth. (Table 44, Figure 26). It was reported that 67.24% of sites with initial PD ≥
5 mm in the control group and 63.96% of sites in the test group reached probing depth ≤ 4 mm.
The subgroup with initial PD ≥ 6 mm showed 52.91% and 54.30% for the control and test
respectively. Only 43.11% of sites with initial PD ≥ 7 mm in the control group reached PD ≤ 4
mm, compared with 48.90% of sites in the test group, although this difference was not
statistically significant.
Calculating the odds ratio for periodontal sites to reach probing depth of 4 mm or less when
treated by the adjunctive therapy with minocycline microspheres compared to the repeated
scaling and root planing, we did not find any statistical significance. For the subgroup with initial
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PD ≥ 5mm odds ratio (OR) was 1.15, for the subgroup with PD ≥ 6 mm OR = 0.85, and OR =
0.79 for the subgroup with initial PD ≥ 7 mm.
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CHAPTER 5. DISCUSSION

5. Discussion
The results of this study showed greater long-term probing depth reduction of 1.50 mm in the
group of patients who received repeated instrumentation within a year, compared with 1.18 mm
of mean probing depth reduction in the Arestin group. Although, being statistically significant
(p-value 1.63e-06), 0.32 mm of difference in probing depth reduction may not have great clinical
significance.

The clinical results in regards to BOP reduction were also superior in the control group showing
8.19% less periodontal sites with positive bleeding on probing, however, test group showed
4.24% more sites with BOP than during the initial presentation.

The dynamics of probing depth throughout follow up appointments revealed different patterns in
test and control groups. For the Arestin group, the greatest amount of PD reduction was observed
on the short-term reevaluation appointment and this result was maintained without any
significant change during long-term follow-up. Conversely, for the control group, the initial
improvement on the short-term reevaluation was followed by some additional PD reduction that
can be noted on the long-term follow-up. The same trend was maintained in all subgroups
(Smokers, Non-Smokers, Diabetes, CVD, Arthritis).

Analyzing periodontal sites with the different initial probing depth we can see a generally greater
change of probing depth in deeper sites. When comparing long-term probing depth reduction in
test and control group, a significant difference was found only in sites with initial PD = 5 mm
(0.91 mm for test the group and 1.19 mm for the control with p-value = 0.0001).
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Subgroups that were filtered according to health history showed more uniform changes in
clinical parameters with the difference that reached level of statistical significance only in shortterm PD reduction between smokers and non-smokers groups. Within the control group, almost
all subgroups had a significantly different clinical responses, which may have been related to the
bigger sample size. Comparing different subgroups of test and control group, statistically
significant difference was found in long-term PD reduction in smokers (0.87 mm for the test
group and 1.51 mm for the control group with p-value < 0.01) and periodontal case type 2 (1.20
mm and 1.48 mm for test and control groups respectively).

It is important to notice that analyzing bleeding on probing for the baseline control group
recorded more sites with positive BOP (37.73%) compared with the test group (26.3%). The
same pattern was observed at the short-term reevaluation where the test group had 15.8% sites
with BOP and for the control group, this number was 24.78%. However, during long-term
follow-up, the difference between groups was insignificant (30.64% of sites in the test group and
29.54% of sites in the control group with p-value = 0.63).

In the test group, bleeding on probing showed a 10.6% of decrease at the short-term reevaluation,
but during long-term follow up there were more sites with BOP than at the baseline (- 4.24% of
BOP reduction). The same trend was observed in all subgroups separated by health history, being
more pronounced in smokers (8.2% of short-term BOP reduction and -14.2% of long-term BOP
reduction) and it was less distinct in non-smokers (Short-term BOP reduction 14.56% and Long-
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term BOP reduction 1.83%) and Diabetes (13.34% of Short-term BOP reduction and 1.34% of
Long-term BOP reduction).

The control group showed 12.95% of BOP reduction at the short-term reevaluation, which
slightly rebounded up to 8.19% of long-term BOP reduction. This same pattern emerged through
all subgroups, except smokers and diabetic patients where BOP slightly improved at the longterm follow-up compared with the short-term observation. For smokers in the control group,
short-term BOP reduction was 10.13% and long-term BOP reduction was 12.16%. For diabetes,
BOP reduction was less than in the general population, but it increased from 4.64% at the shortterm examination to 5.77% at the long-term follow-up. Characteristics of BOP are summarized
in the Table 47.

Generally, significantly more periodontal sites improved to ≥ 1 and ≥ 2 in the control group than
in the test group. For clinical response ≥1 mm it was 80.23% sites versus 70.71% sites for
control and test groups respectively. Clinical response ≥ 2 mm was 52.35% of sites in the control
group and 42.96% of sites in the test group. When we compared subgroups stratified by initial
probing depth, the difference between subgroups with PD ≤ 6 mm and PD ≤ 7 mm was
insignificant. Also, the percentage of sites that reached PD ≤ 4 mm which is considered as the
clinical sign of disease control, there was no significant difference between groups.

It is important to mention that the retrospective nature of our study restricts our ability to design
the ideal control because rather than enrolling patients and randomizing them into groups
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balanced by age, health history, and clinical presentation, we are reviewing clinical data related
to different treatment modalities.

Our test group included patients who received adjunctive therapy with minocycline microspheres
and non-surgical treatment of periodontal disease had some degree of heterogeneity. This is
because Arestin is used at the initial stage of periodontal treatment as well as at the reevaluation
and maintenance stages. The common indication for use of local delivery minocycline as the
adjunctive therapy is the non-responding sites after initial periodontal therapy or progressing
periodontal sites. Although some researchers exclude progressing sites from analysis (Smiley et
al., 2015), our objective was to obtain evidence about the efficacy of adjunctive therapy as
closely mimic implementation from real practice as possible.

The fact that many patients from the Arestin group previously received initial periodontal
therapy led us to the decision to match the test group with the clinical data from patients who
received repeated scaling and root planing. However, we know from the classic study published
by the Loma Linda group in 1984 that there’s no significant improvement in clinical parameters
after the first round of SRP (Badersten et al., 1984), patients who were included in our study had
periodontal therapy mainly on their molar teeth that is different from a patient clinical profile in
the classic study.

Although we attempted to match the test and control group, there were some differences in a
clinical presentation at the baseline. For example, the test group had more patients with
cardiovascular disease (42.22% vs 27.77%), more patients with periodontal case type 2 (63.89%
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vs 44.46%). The control group had significantly more smokers (34.48% compared to 29.44%)
and clinically, there was a higher percentage of sites with BOP (37.73% vs 26.4%). Additionally,
the test group received adjunctive therapy with Arestin on isolated periodontal sites compared
with SRP in the control group that extended up to a whole quadrant in many patients.

It was also decided to keep the sample size of convenience when all available subjects are
analyzed that led to unequal sample size in the test and control groups. The rationale was that the
sample size of the control group provides more statistical power for the analysis of clinical
response between different subgroups. Despite the differences, on the site level distribution of
sites by the initial probing depth was similar in test and control groups.

It may be beneficial to provide a comparison with the clinical efficacy of the single
instrumentation which can be done in future studies.
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TABLES

Number of patients

1120

Female

582

Male

538

AVG age

62

Min age

14

Max age

93

Race - Black

462

Race - Hawaiian

75

Race - White

167

Race - Asian

59

Race - Other

45

Race - Unreported

310

ASAI

194

ASAIIA

323

ASAIIB

253

ASAIII

163

Smoker "Yes"

385

Smoker "No"

693

Smoker Unreported

32

Diabetes

181

HbA1c reported

54

HBA1C>7

49

CVD

311

Arthritis

324

ADA Type II

498

ADA Type III

341

ADA Type IV

2

ADA unreported

280

N of BMI reported

7

Table 1. Demographics of the Control Group.
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Initial

Short-term

Long-term

Mean PD

5.62

4.42

4.12

SD

0.98

1.47

1.53

VAR

0.96

2.15

2.35

SE

0.01

0.01

0.01

Table 2. Dynamics of probing depth for the Control Group.

Short-term

Long-term

Mean PD red

1.20

1.50

Sd

1.36

1.54

Var

1.85

2.36

SE

0.01

0.01

Table 3. Probing depth reduction for the Control Group

Mean

1.19785373

Standard Error

0.01290851

Median

1

Mode

1

Standard Deviation

1.35932157

Sample Variance

1.84775513

Kurtosis

1.37671756

Skewness

0.01778748

Range

15

Minimum

-7

Maximum

8

Table 4. Descriptive statistics of mean short-term probing depth reduction in the Control Group.
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Mean

1.50175597

Standard Error

0.01458985

Median

2

Mode

2

Standard Deviation

1.53748245

Sample Variance

2.36385228

Kurtosis

2.23449627

Skewness

-0.3865136

Range

16

Minimum

-9

Maximum

7

Table 5. Descriptive statistics of mean long-term probing depth reduction in the Control Group.

Table 6. Results of t-test comparing mean short-term and long-term probing depth reduction in the
Control Group.
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Table 8. Results of the ANOVA test for the Long-term probing depth reduction in the Control Group

Table 7. Results of the ANOVA test for the Short-term PD reduction in the Control Group.
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Short-Term PD
reduction

Long-term PD
reduction

All population

1.20 (±0.01)

1.50 (±0.01)

Smokers

1.15 (±0.02)

1.51 (±0.02)

Non-Smokers

1.23 (±0.02)

1.52 (±0.02)

Diabetes

1.11 (±0.03)

1.44 (±0.04)

CVD

1.18 (±0.02)

1.44 (±0.02)

Arthritis

1.15 (±0.02)

1.38 (±0.02)

Table 9. Mean probing depth reduction for different subgroups within the Control Group.
P-value

Smokers
Short
Short

All population

Long

Short

p<0.01

Long

p>0.05

Non-Smokers
Long
All population

Short
Long

p>0.05

p>0.05

p>0.05

p<0.01
p>0.05 p<0.01

Table 10. Table of p-values for pairwise comparison of mean PD reduction for subgroups within the
Control Group.
P-value

Diabetes
Short
Short

All population

Long

Short

p<0.01

p<0.01

Long

Diabetes
Long

p<0.05

p>0.05

Short

p<0.01

p<0.01

All population
Long

p>0.05

p<0.01

Table 11. Table of p-values for pairwise comparison of mean PD reduction for subgroups within the
Control Group.
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P-value

CVD
Short
Short

CVD

All population

All population

Long

Short

p<0.01

p>0.05

Long

Long

p<0.01

p>0.05

Short

p>0.05

p<0.01

Long

p>0.05

p<0.01

Table 12. Table of p-values for pairwise comparison of mean PD reduction for subgroups within the
Control Group.

P-value

Arthritis
Short
Short

All population

Long

Short

p<0.01

p>0.05

Long

Arthritis
Long

p<0.01

p<0.01

Short

p>0.05

p<0.01

All population
Long

p<0.01

p<0.01

Table 13. Table of p-values for pairwise comparison of mean PD reduction for subgroups within the
Control Group.

Short-Term PD reduction

Long-term PD reduction

All population

1.20 (±0.01)

1.50 (±0.01)

ADA Case Type 2

1.24 (±0.02)

1.48 (±0.02)

ADA Case Type 3

1.16 (±0.02)

1.48 (±0.02)

Table 14. Mean probing depth reduction for periodontal case type subgroups within the Control Group

40

P-value

All population
Short
Short

Type 2

Long

Short

p<0.01

p>0.05

Type 3

Long

Short

Long

p>0.05

All population
Long

p<0.01

p>0.05

Short

p>0.05

p<0.01

p>0.05
p>0.05

Type 2
Long
Short

p>0.05
p>0.05

p<0.01

p>0.05

p>0.05

p<0.01

Type 3
Long

p>0.05

p>0.05

p<0.01

Table 15. Table of p-values for pairwise comparison of mean PD reduction for subgroups within the
Control Group.
5 mm

6 mm

7 mm

8 mm

9 mm

Mean PD red

0.99

1.31

1.65

2.04

2.35

SE

0.01

0.03

0.05

0.08

0.13

N

6967

2356

1047

518

242

Table 16. Mean short-term probing depth reduction for the control group stratified by the initial probing
depth.
5 mm

6 mm

7 mm

8 mm

9 mm

Mean PD red

1.19

1.69

2.16

2.72

3.26

SE

0.02

0.03

0.06

0.09

0.15

N

6967

2356

1047

518

242

Table 17. Mean long-term probing depth reduction for the control group stratified by the initial probing
depth.
≥ 5 mm

≥ 6 mm

≥ 7 mm

≥ 1mm

80.23%

82.08%

83.23%

≥ 2 mm

52.35%

65.00%

70.95%

Table 18. Clinical response of sites with initial probing depth in the Control Group
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≥ 5 mm

≥ 6 mm

≥ 7 mm

Mean PD red

1.50

2.02

2.47

SE

0.01

0.03

0.05

N

11130

4163

1807

Table 19. Mean long-term probing depth reduction for sites with different initial probing depth.
Number of
patients

540

Female

298

Male

242

AVG age

61.5

Min age

17

Max age

93

Race - Black

206

Race - Hawaiian

72

Race - White

71

Race - Asian

24

Race - Other

15

Race Unreported

150

ASAI

84

ASAIIA

269

ASAIIB

116

ASAIII

66

42

Smoker "Yes"

159

Smoker "No"

352

Smoker Unreported

64

Diabetes

91

HbA1c reported

58

HBA1C>7

18

CVD

228

Arthritis

178

ADA Type II

345

ADA Type III

133

ADA unreported

60

N of BMI reported

26

BMI average

28.48

Table 20. Demographics of the Test group.

Initial

Short-term

Long-term

Mean PD

5.41

4.27

4.23

SD

0.73

1.30

1.44

VAR

0.53

1.70

2.07

SE

0.03

0.06

0.06

Table 21. Dynamics of probing depth during the treatment for the Test group.

Short-term

Long-term

Mean PD red

1.14

1.18

Sd

1.28

1.49

Var

1.63

2.21

SE

0.06

0.07

Table 22. Probing depth reduction for the Test group.
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Short-term PD reduction

Mean

1.13513514

Standard Error

0.05602336

Median

1

Mode

1

Standard Deviation

1.2750701

Sample Variance

1.62580375

Kurtosis

1.64351786

Skewness

0.57133407

Range

10

Minimum

-3

Maximum

7

Table 23 and 24. Descriptive statistics for the short-term PD reduction for the Test group
Long-term PD reduction

Mean

1.17760618

Standard Error

0.06529175

Median

1

Mode

1

Standard Deviation

1.4860149

Sample Variance

2.20824029

Kurtosis

0.52868132

Skewness

-0.2894718

Range

9

Minimum

-4

Maximum

5

Table 24. Descriptive statistics for long-term PD reduction for the Test group.
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Table 25. T-test to compare short-term and long-term probing depth reduction in the test group.

Tables 26 and 27. Results of ANOVA test for short-term and long-term PD reduction in the Test group.
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Short-Term PD reduction

Long-term PD reduction

All population

1.14 (±0.06)

1.18 (±0.07)

Smokers

1.13 (±0.08)

0.87 (±0.11)

Non-Smokers

1.08 (±0.07)

1.29 (±0.09)

Diabetes

1.21 (±0.15)

1.37 (±0.17)

CVD

1.08 (±0.08)

1.33 (±0.1)

Arthritis

1.38 (±0.1)

1.26 (±0.02)

Table 28. Mean probing depth reduction for different subgroups within the Test Group.

P-value

Smokers
Short
Short

Long

p>0.05

All population
Short

Long

p>0.05

Non-Smokers
Long
Short

p<0.01

p>0.05

p>0.05

p>0.05

All population
Long

p>0.05

p>0.05

Table 29. Table of p-values for pairwise comparison of mean PD reduction for Smokers and Nonsmokers subgroups within the Test Group.

P-value

Diabetes
Short

Diabetes

All population

Short

All population

Long

Short

p>0.05

p>0.05

Long

Long

p>0.05

p>0.05

Short

p>0.05

p>0.05

Long

p>0.05

p>0.05

Table 30. Table of p-values for pairwise comparison of mean PD reduction for Diabetes subgroup within
the Test Group.
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P-value

CVD
Short
Short

CVD

All population

All population
Long

Short

p>0.05

p>0.05

Long

Long

p>0.05

p>0.05

Short

p>0.05

p>0.05

Long

p>0.05

p>0.05

Table 31. Table of p-values for pairwise comparison of mean PD reduction for cardiovascular disease
subgroup within the Test Group.
P-value

Arthritis
Short
Short

Arthritis

All population

All population

Long

Short

p>0.05

p>0.05

Long

Long

p>0.05

p>0.05

Short

p>0.05

p>0.05

Long

p>0.05

p>0.05

Table 32. Table of p-values for pairwise comparison of mean PD reduction for arthritis subgroup within
the Test Group.
Short-Term PD reduction

Long-term PD reduction

All population

1.14 (±0.06)

1.18 (±0.07)

ADA Case Type 2

1.13 (±0.06)

1.19 (±0.09)

ADA Case Type 3

1.20 (±0.14)

1.20 (±0.14)

Table 33. Mean probing depth reduction for subgroup based on case type within the Test Group.
P-value

All population
Short

All population

Type 2

Type 3

Short

Type 2

Long

Short

p>0.05

p>0.05

Long

p>0.05

p>0.05

Short

p>0.05

p>0.05

Short

p>0.05
p>0.05

Short

Long

p>0.05

Long

Long

Type 3

p>0.05
p>0.05

p>0.05

p>0.05

p>0.05

p>0.05

Long
p>0.05
p>0.05 p>0.05
Table 34. Table of p-values for pairwise comparison of mean PD reduction for arthritis subgroup within
the Test Group.
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P-value

TEST

CONTROL

Smokers
Short

Long

Diabetes
Short

Long

CVD
Short

Long

Arthritis
Short

Long

Case Type 2

Case Type 3

Short

Short

Long

Long

Short p>0.05
Smokers
Long
Diabetes

CVD

Arthritis

p<0.01

Short

p>0.05

Long

p>0.05

Short

p>0.05

Long

p>0.05

Short

p>0.05

Long

p>0.05

Case Type Short
2
Long

p>0.05
p<0.01

Case Type Short
3
Long

p>0.05
p>0.05

Table 35. Table of p-values for inter-group comparison.
5 mm

6 mm

7 mm

8 mm

9 mm

Mean PD red

0.95

1.38

1.76

2.5

5

SE

0.06

0.13

0.31

0.7

N

368

104

34

12

1

Table 36. Mean short-term probing depth reduction in the Test Group stratified by the initial PD.
5 mm

6 mm

7 mm

8 mm

9 mm

Mean PD red

0.92

1.53

2.5

2.1

5

SE

0.07

0.15

0.31

0.6

N

368

104

34

14

1

Table 37. Mean long-term probing depth reduction in the Test Group stratified by the initial PD.
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≥ 5 mm

≥ 6 mm

≥ 7 mm

≥ 1mm

70.71%

77.48%

80.85%

≥ 2 mm

42.96%

60.92%

70.21%

Table 38. Clinical response for sites with different initial PD in the Test group.
≥ 5 mm

≥ 6 mm

≥ 7 mm

Mean PD red

1.18

1.81

2.45

SE

0.07

0.14

0.27

N

519

151

47

Table 39. Mean long-term PD reduction for sites with different initial PD in the Test group.

Table 40. Results of the t-test comparing short-term PD reduction for control and test groups.

Table 41. Results of the t-test comparing long-term PD reduction for control and test groups.
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≥ 5 mm

≥ 6 mm

≥ 7 mm

Control Group

80.23%

82.08%

83.83%

Test Group

70.71%

77.48%

80.85%

Table 42. Comparison of the clinical response ≥ 1 mm in test and control groups for subgroups with
different initial PD.
≥ 5 mm

≥ 6 mm

≥ 7 mm

Control Group

52.35%

65.00%

70.95%

Test Group

42.96%

60.92%

70.21%

Table 43. Comparison of the clinical response ≥ 2 mm in test and control groups for subgroups with
different initial PD.
≥ 5 mm

≥ 6 mm

≥ 7 mm

Control Group

67.24%

52.91%

43.11%

Test Group

63.96%

54.30%

48.90%

Table 44. Percentage of sites that reached PD ≤ 4 mm in test and control groups for subgroups with
different initial PD.
≥ 5 mm

≥ 6 mm

≥ 7 mm

Odds Ratio

1.15

0.85

0.79

CI 95%

0.96 - 1.39

0.6 - 1.19

0.44 - 1.41

P value

0.12

0.34

0.42

Table 45. Odds ratio for periodontal sites with different initial probing depth to reach PD ≤ 4 mm when
treated with Arestin compared to repeated SRP.
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Test n=540

Control n=1120

Proportion test
P-value

Avg age

61.5

62

Male

44.81%

48.04%

Female

55.19%

51.96%

ASA 1

15.56%

17.32%

0.4

ASA 2

71.3%

51.43%

2.2e-16

ASA 3

12.22%

14.55%

0.22

Smoking

29.44%

34.38%

0.05

Diabetes

16.85%

16.16%

0.78

CVD

42.22%

27.77%

5.35e-09

Arthritis

32.96%

29.93%

0.1

Case type 2

63.89%

44.46%

1.79e-13

Case type 3

24.63%

30.45%

0.76

BOP initial

26.4%

37.73%

0.24

Table 46. Comparison of demographics in test and control groups.
Groups

Initial BOP

Short-term BOP

Long-term

Short-term
reduction

Long-term
reduction

TG

26.45%

15.8%

30.64%

10.6%

- 4.24%

CG

37.73%

24.78%

29.54%

12.95%

8.19%

P-value

<0.0001

<0.0001

0.63

TG

19.13%

10.93%

33.33%

8.2%

- 14.20%

CG

38.53%

28.4%

26.37%

10.13%

12.16%

P-value

<0.001

<0.001

0.05

TG

30.77%

16.12%

28.94%

14.56%

1.83%

CG

38.67%

23.23%

31.35%

15.44%

7.32%

P-value

0.01

<0.01

0.44

TG

30.67%

17.33%

29.33%

13.34%

1.34%

CG

31.5%

26.86%

25.73%

4.64%

5.77%

P-value

0.98

0.09

0.6

All population

Smokers

Non-Smokers

Diabetes

CVD
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TG

22.12%

17.79%

26.44%

4.33%

- 4.32%

CG

37.44%

24.50%

29.61%

12.94%

7.83%

p-value

<0.0001

0.03

0.37

TG

18.88%

11.73%

24.49%

7.15%

-5.61

CG

34.89%

20.39%

34.92%

14.5%

-0.03

p-value

<0.0001

<0.01

<0.01

TG

25.29%

12.5%

27.33%

12.79%

-2.04%

CG

35.55%

21.33%

25.0%

14.22%

10.55%

p-value

<0.001

0.0001

0.38

TG

29.5%

23.0%

35.25%

6.5%

-2.75%

CG

35.28%

23.33%

30.47%

11.95%

4.81%

p-value

0.19

1

0.26

Arthritis

Type2

Type 3

Table 47. Comparison of BOP in all subgroups within test and control groups.
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FIGURES

Figure 1. Timeline of treatment for the Control group.

Figure 2. Timeline of treatment for the Test group.

Figure 3. Structure of data.
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Figure 4. Histogram of age for the Control group.

Figure 5. Distribution of patients by ASA type in the Control group.

Figure 6. Histogram of teeth that received treatment in the Control group.
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Figure 7. Histogram of treated periodontal sites by the initial probing depth in the
Control group.

Figure 8. Chart of locations for treated sites in the Control group (1 and 3 indicate
interproximal sites, 2 – mid-buccal and mid-lingual).

Figure 9. Box plot of PD dynamics in the Control group.
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Figure 10. Boxplot for PD reduction for the Control group.

Figure 11. Boxplot for short-term PD reduction stratified by the initial PD in the Control group.

Figure 12. Boxplot for long-term PD reduction stratified by the initial PD in the Control group.

56

Figure 13. Clinical response for subgroups with different initial PD in the Control group.

Figure 14. Histogram of age in the Test group.

Figure 15. Distribution of Test group patients by the ASA type.

Figure 16. Histogram of treated teeth numbers in the Test group.
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Figure 17. Histogram of initial probing depth for treated sites in the Test group.

Figure 18. Chart showing location of treated sites in the Test group (1 and 3 indicate interproximal sites, 2
– mid-buccal and mid-lingual).

Figure 19. Boxplot for PD dynamics in the Test group.
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Figure 20. Boxplot for PD reduction in the Test group.

Figure 21. Boxplot of short-term PD reduction in the Test group stratified by the initial PD.

Figure 22. Boxplot of long-term PD reduction in the Test group stratified by the initial PD.
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Figure 23. Clinical response for different subgroups based on initial PD in the Test group.

Figure 24. Comparison of clinical response ≥ 1 mm in test and control groups in subgroups with different
initial PD (CG – Control group, TG – Test group).

Figure 25. Comparison of clinical response ≥ 2 mm in test and control groups in subgroups with different
initial PD (CG – Control group, TG – Test group).
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Figure 26. Comparison of percentage of sites reached PD ≤ 4 mm in test and control groups.
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